van Furth R, Cohn ZA, 1968, The origin and kinetics of mononuclear phagocytes. J Exp Med, 128: 415–435.

https://doi.org/10.1084/jem.128.3.415 

Engblom C, Pfirschke C, Pittet MJ, 2016, The role of myeloid cells in cancer therapies. Nat Rev Cancer, 16: 447–462.

https://doi.org/10.1038/nrc.2016.54

Pollard JW, 2004, Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4: 71–78.

https://doi.org/10.1038/nrc1256

Sica A, Schioppa T, Mantovani A, et al., 2006, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer, 42: 717–727.

https://doi.org/10.1016/j.ejca.2006.01.003

Yunna C, Mengru H, Lei W, et al., 2020. Macrophage M1/ M2 polarization. Eur J Pharmacol, 877: 173090.

https://doi.org/10.1016/j.ejphar.2020.173090

Krieg C, Nowicka M, Guglietta S, et al., 2018, High-dimensional Single-cell Analysis Predicts Response to Anti-PD-1 Immunotherapy. Nat Med, 24: 144–153.

https://doi.org/10.1038/nm.4466

Roberts SA, Waziri AE, Agrawal N, 2016, Development of a single-cell migration and extravasation platform through selective surface modification. Anal Chem, 88:2770–2776.

https://doi.org/10.1021/acs.analchem.5b04391

Chen YC, Allen SG, Ingram PN, et al., 2015, Single-cell migration chip for chemotaxis-based microfluidic selection of heterogeneous cell populations. Scientific reports, 5: 9980.

Zhuang J, Wu Y, Chen L, et al., 2018, Single-cell mobility analysis of metastatic breast cancer cells. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 5: 1801158.

https://doi.org/10.1002/advs.201801158

Trapnell C, 2015, Defining cell types and states with single-cell genomics. Genome Res, 25: 1491–1498.

Grün D, van Oudenaarden A, 2015, Design and analysis of single-cell sequencing experiments. Cell, 163: 799–810.

https://doi.org/10.1016/j.cell.2015.10.039

Topalian SL, Hodi FS, Brahmer JR, et al., 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366: 2443–2454.

https://doi.org/10.1056/NEJMoa1200690

Powles T, Eder JP, Fine GD, et al., 2014, MPDL3280A (anti- PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515: 558–562.

https://doi.org/10.1038/nature13904

Rizvi NA, Hellmann MD, Snyder A, et al., 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York), 348: 124–128.

https://doi.org/10.1126/science.aaa1348 

Ansell SM, Lesokhin AM, Borrello I, et al., 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med, 372(4): 311–319.

Robert C, Schachter J, Long GV, et al., 2015, Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med, 372(26): 2521–2532.

https://doi.org/10.1056/NEJMoa1503093

Ostrand-Rosenberg S, Sinha P, 2009, Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol (Baltimore, Md. 1950), 182(8): 4499–4506.

https://doi.org/10.4049/jimmunol.0802740

Auffray C, Sieweke MH, Geissmann F, 2009, Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol, 27: 669–692.

https://doi.org/10.1146/annurev.immunol.021908.132557

Shi C, Pamer EG, 2011, Monocyte recruitment during infection and inflammation. Nat Rev Immunol, 11(11): 762–774.

https://doi.org/10.1038/nri3070

Ziegler-Heitbrock L, Ancuta P, Crowe S, et al., 2010, Nomenclature of monocytes and dendritic cells in blood. Blood, 116(16): e74–e80.

https://doi.org/10.1182/blood-2010-02-258558

Auffray C, Fogg D, Garfa M, et al., 2007, Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science (New York), 317(5838): 666–670.

https://doi.org/10.1126/science.1142883

Movahedi K, Laoui D, Gysemans C, et al., 2010, Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res, 70(14): 5728–5739.

https://doi.org/10.1158/0008-5472.CAN-09-4672

Mildner A, Schönheit J, Giladi A, et al., 2017, Genomic characterization of murine monocytes reveals C/EBPβ transcription factor dependence of Ly6C cells. Immunity, 46(5): 849–862.e7.

https://doi.org/10.1016/j.immuni.2017.04.018

van Galen P, Hovestadt V, Wadsworth Ii MH, et al., 2019, Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell, 176(6): 1265–1281.e1224.

https://doi.org/10.1016/j.cell.2019.01.031

Zilionis R, Engblom C, Pfirschke C, et al., 2019, Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity, 50(5): 1317–1334.e1310.

https://doi.org/10.1016/j.immuni.2019.03.009

Puram SV, Tirosh I, Parikh AS, et al., 2017, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell, 171(7): 1611–1624.e24.

https://doi.org/10.1016/j.cell.2017.10.044

Passlick B, Flieger D, Ziegler-Heitbrock HW, 1989, Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood, 74(7): 2527–2534.

Olingy CE, Dinh HQ, Hedrick CC, 2019, Monocyte heterogeneity and functions in cancer. J Leukocyte Biol, 106(2): 309–322.

https://doi.org/10.1002/JLB.4RI0818-311R

Villani AC, Satija R, Reynolds G, et al., 2017, Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (New York), 356(6335): eaah4573.

https://doi.org/10.1126/science.aah4573

Qian BZ, Li J, Zhang H, et al., 2011, CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355): 222–225.

https://doi.org/10.1038/nature10138

Schmall A, Al-Tamari HM, Herold S, et al., 2015, Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med., 191(4): 437–447.

https://doi.org/10.1164/rccm.201406-1137OC

Li X, Yao W, Yuan Y, et al., 2017, Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut, 66(1): 157–167.

https://doi.org/10.1136/gutjnl-2015-310514

Gordon IO, Freedman RS, 2006, Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res, 12(5): 1515–1524.

https://doi.org/10.1158/1078-0432.CCR-05-2254

Sheng J, Chen Q, Soncin I, et al., 2017, A discrete subset of monocyte-derived cells among typical conventional Type 2 dendritic cells can efficiently cross-present. Cell Rep, 21(5): 1203–1214.

https://doi.org/10.1016/j.celrep.2017.10.024

Hanna RN, Cekic C, Sag D, et al., 2015, Patrolling monocytes control tumor metastasis to the lung. Science (New York), 350(6263): 985–990.

https://doi.org/10.1126/science.aac9407

Romano E, Kusio-Kobialka M, Foukas PG, et al., 2015, Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A, 112(19): 6140–6145.

https://doi.org/10.1073/pnas.1417320112

De Palma M, Venneri MA, Galli R, et al., 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 8(3): 211–226.

https://doi.org/10.1016/j.ccr.2005.08.002

Venneri MA, De Palma M, Ponzoni M, et al., 2007, Identification of proangiogenic TIE2–expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 109(12): 5276–5285.

https://doi.org/10.1182/blood-2006-10-053504

Duan Z, Luo Y, 2021, Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther, 6(1): 127.

https://doi.org/10.1038/s41392-021-00506-6

Wynn TA, Chawla A, Pollard JW, 2013, Macrophage biology in development, homeostasis and disease. Nature, 496(7446): 445–455.

https://doi.org/10.1038/nature12034

Ginhoux F, Jung S, 2014, Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol, 14(6): 392–404.

https://doi.org/10.1038/nri3671

Fogg DK, Sibon C, Miled C, et al., 2006, A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science (New York), 311(5757): 83–87.

https://doi.org/10.1126/science.1117729

Lee J, Breton G, Oliveira TY, et al., 2015, Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J Exp Med, 212(3): 385–399.

https://doi.org/10.1084/jem.20141442

Menezes S, Melandri D, Anselmi G, et al., 2016, The heterogeneity of Ly6C monocytes controls their differentiation into iNOS macrophages or monocyte-derived dendritic cells. Immunity, 45(6): 1205–1218.

https://doi.org/10.1016/j.immuni.2016.12.001

Gabrilovich DI, Bronte V, Chen SH, et al., 2007, The terminology issue for myeloid–derived suppressor cells. Cancer Res, 67(1): 425; author reply 426.

https://doi.org/10.1158/0008-5472.CAN-06-3037

Veglia F, Perego M, Gabrilovich D, 2018, Myeloid-derived suppressor cells coming of age. Nat Immunol, 19(2): 108–119.

https://doi.org/10.1038/s41590-017-0022-x

Filipazzi P, Valenti R, Huber V, et al., 2007, Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol, 25(18): 2546–2553.

https://doi.org/10.1200/JCO.2006.08.5829

Zea AH, Rodriguez PC, Atkins MB, et al., 2005, Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res, 65(8): 3044–3048.

https://doi.org/10.1158/0008-5472.CAN-04-4505

Srivastava MK, Bosch JJ, Thompson JA, et al., 2008, Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother, 57(10): 1493–1504.

https://doi.org/10.1007/s00262-008-0490-9

Hoechst B, Ormandy LA, Ballmaier M, et al., 2008, A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+) Foxp3(+) T cells. Gastroenterology, 135(1): 234–243.

https://doi.org/10.1053/j.gastro.2008.03.020

Canè S, Ugel S, Trovato R, et al., 2019, The endless saga of monocyte diversity. Front Immunol, 10: 1786.

https://doi.org/10.3389/fimmu.2019.01786

Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, et al., 2020, Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer, 8(2): e001223.

https://doi.org/10.1136/jitc-2020-001223

Hartwig T, Montinaro A, von Karstedt S, et al., 2017, The TRAIL-induced cancer secretome promotes a tumor- supportive immune microenvironment via CCR2. Mol Cell, 65(4): 730–742.e5.

https://doi.org/10.1016/j.molcel.2017.01.021

Hettinger J, Richards DM, Hansson J, et al., 2013, Origin of monocytes and macrophages in a committed progenitor. Nat Immunol, 14(8): 821–830.

https://doi.org/10.1038/ni.2638

Kawamura S, Onai N, Miya F, et al., 2017, Identification of a human clonogenic progenitor with strict monocyte differentiation potential: A counterpart of mouse cMoPs. Immunity, 46(5): 835–848.e4.

https://doi.org/10.1016/j.immuni.2017.04.019

Drissen R, Buza-Vidas N, Woll P, et al., 2016, Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. Nat Immunol, 17(6): 666–676.

https://doi.org/10.1038/ni.3412

Sasmono RT, Oceandy D, Pollard JW, et al., 2003, A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood, 101(3): 1155–1163.

https://doi.org/10.1182/blood-2002-02-0569

Van Dyken SJ, Locksley RM, 2013, Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: Roles in homeostasis and disease. Annu Rev Immunol, 31: 317–343.

https://doi.org/10.1146/annurev-immunol-032712-095906

Nirschl CJ, Suárez-Fariñas M, Izar B, et al., 2017, IFNγ- dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell, 170(1): 127–141.e115.

https://doi.org/10.1016/j.cell.2017.06.016

Long AH, Highfill SL, Cui Y, et al., 2016, Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res, 4(10): 869–880.

https://doi.org/10.1158/2326-6066.CIR-15-0230

Michielon E, González ML, Burm JL, et al., Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. Cancer Immunol Immunother, 69(11): 2319–2331.

https://doi.org/10.1007/s00262-020-02626-4

Sander J, Schmidt SV, Cirovic B, et al., 2017, Cellular differentiation of human monocytes is regulated by time-dependent interleukin-4 signaling and the transcriptional regulator NCOR2. Immunity, 47(6): 1051–1066.e12.

https://doi.org/10.1016/j.immuni.2017.11.024 

Shen CK, Huang BR, Yeh WL, et al., 2021, Regulatory effects of IL-1β in the interaction of GBM and tumor-associated monocyte through VCAM-1 and ICAM-1. Eur J Pharmacol, 905: 174216.

https://doi.org/10.1016/j.ejphar.2021.174216

Franklin RA, Liao W, Sarkar A, et al., 2014, The cellular and molecular origin of tumor-associated macrophages. Science (New York), 344(6186): 921–925.

https://doi.org/10.1126/science.1252510

Jenkins SJ, Ruckerl D, Cook PC, et al., 2011, Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science (New York), 332(6035): 1284–1288.

https://doi.org/10.1126/science.1204351

Orecchioni M, Ghosheh Y, Pramod AB, et al., 2019, Macrophage polarization: Different gene signatures in M1(LPS+) vs. classically and M2(LPS–) vs. alternatively activated macrophages. Front Immunol, 10: 1084.

https://doi.org/10.3389/fimmu.2019.01084

Okabe Y, Medzhitov R, 2014, Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell, 157(4): 832–844.

https://doi.org/10.1016/j.cell.2014.04.016 

Devalaraja S, To TK, Folkert IW, et al., 2020, Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression. Cell, 180(6): 1098–1114.e16.

https://doi.org/10.1016/j.cell.2020.02.042

Chun E, Lavoie S, Michaud M, et al., 2015, CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep, 12(2): 244–257.

https://doi.org/10.1016/j.celrep.2015.06.024

Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev, 21(1): 41–48.

https://doi.org/10.1016/j.cytogfr.2009.11.009

Ma RY, Zhang H, Li XF, et al., 2020, Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J Exp Med, 217(11): e20191820.

https://doi.org/10.1084/jem.20191820

Cortez-Retamozo V, Etzrodt M, Newton A, et al., 2012, Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A, 109(7): 2491–2496.

https://doi.org/10.1073/pnas.1113744109

Yeap WH, Wong KL, Shimasaki N, et al., 2016, CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep, 6: 34310.

https://doi.org/10.1038/srep34310

Kusmartsev S, Nefedova Y, Yoder D, et al., 2004, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (Baltimore, Md. 1950), 172(2): 989–999.

https://doi.org/10.4049/jimmunol.172.2.989

Bronte V, Serafini P, Mazzoni A, et al., 2003, L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol, 24(6): 302–306.

https://doi.org/10.1016/s1471-4906(03)00132-7

Baniyash M, 2004, TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol, 4(9): 675–687.

https://doi.org/10.1038/nri1434

Jakubzick CV, Randolph GJ, Henson PM, 2017, Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol, 17(6): 349–362.

https://doi.org/10.1038/nri.2017.28

Ma Y, Adjemian S, Mattarollo SR, et al., 2013, Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity, 38(4): 729–741.

https://doi.org/10.1038/nri.2017.28

Kuhn S, Yang J, Ronchese F, 2015, Monocyte-derived dendritic cells are essential for CD8(+) T cell activation and antitumor responses after local immunotherapy. Front Immunol, 6: 584.

https://doi.org/10.3389/fimmu.2015.00584

Zhu C, Kros JM, Cheng C, et al., 2017, The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro Oncol, 19(11): 1435–1446.

https://doi.org/10.1093/neuonc/nox081

Chittezhath M, Dhillon MK, Lim JY, et al., 2014, Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity, 41(5): 815–829.

https://doi.org/10.1016/j.immuni.2014.09.014

De Palma M, Venneri MA, Roca C, et al, 2003, Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med, 9(6): 789–795.

https://doi.org/10.1038/nm871

Shojaei F, Wu X, Malik AK, et al., 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol, 25(8): 911–920.

https://doi.org/10.1038/nbt1323

Kaplan RN, Riba RD, Zacharoulis S, et al., 2005, VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069): 820–827.

https://doi.org/10.1038/nature04186

Matsubara T, Kanto T, Kuroda S, et al., 2013, TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology, 57(4): 1416–1425.

https://doi.org/10.1002/hep.25965

Harney AS, Arwert EN, Entenberg D, et al., 2015, Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov, 5(9): 932–943.

https://doi.org/10.1158/2159-8290.CD-15-0012

Lu P, Weaver VM, Werb Z, 2012, The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol, 196(4): 395–406.

https://doi.org/10.1083/jcb.201102147

Naba A, Clauser KR, Hoersch S, et al., 2012, The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics, 11(4): M111.014647.

https://doi.org/10.1074/mcp.M111.014647

Kessenbrock K, Plaks V, Werb Z, 2010, Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141(1): 52–67.

https://doi.org/10.1016/j.cell.2010.03.015

Mason SD, Joyce JA, 2011, Proteolytic networks in cancer. Trends Cell Biol, 21(4): 228–237.

https://doi.org/10.1016/j.tcb.2010.12.002

Afik R, Zigmond E, Vugman M, et al., 2016, Tumor macrophages are pivotal constructors of tumor collagenous matrix. J Exp Med, 213(11): 2315–2331.

https://doi.org/10.1084/jem.20151193

Madsen DH, Jürgensen HJ, Siersbæk MS, et al., 2017, Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Rep, 21(13): 3662–3671.

https://doi.org/10.1016/j.celrep.2017.12.011

Madsen DH, Leonard D, Masedunskas A, et al., 2013, M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol, 202(6): 951–966.

https://doi.org/10.1083/jcb.201301081

Guilliams M, Ginhoux F, Jakubzick C, et al., 2014, Dendritic cells, monocytes and macrophages: A unified nomenclature based on ontogeny. Nat Rev Immunol, 14(8): 571–578.

https://doi.org/10.1038/nri3712

DeNardo DG, Ruffell B, 2019, Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol, 19(6): 369–382.

https://doi.org/10.1038/s41577-019-0127-6

Zhu Y, Herndon JM, Sojka DK, et al., 2017, Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity, 47(2): 323–338.e6.

https://doi.org/10.1016/j.immuni.2017.07.014

Sica A, Bronte V, 2007, Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Investig, 117(5): 1155–1166.

https://doi.org/10.1172/JCI31422

Yin M, Li X, Tan S, et al., 2016, Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Investig, 126(11): 4157–4173.

https://doi.org/10.1172/JCI87252

Richards DM, Hettinger J, Feuerer M, 2013, Monocytes and macrophages in cancer: development and functions. Cancer Microenviron, 6(2): 179–191.

https://doi.org/10.1007/s12307-012-0123-x

Martinez FO, Helming L, Gordon S, 2009, Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol, 27: 451–483.

https://doi.org/10.1146/annurev.immunol.021908.132532

Mantovani A, Sozzani S, Locati M, et al., 2002, Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 23(11): 549–555.

https://doi.org/10.1016/s1471-4906(02)02302-5

Minopoli M, Sarno S, Di Carluccio G, et al., 2020, Inhibiting monocyte recruitment to prevent the pro-tumoral activity of tumor-associated macrophages in chondrosarcoma. Cells, 9(4): 1062.

https://doi.org/10.3390/cells9041062 

Murray PJ, Allen JE, Biswas SK, et al., 2014, Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 41(1): 14–20.

https://doi.org/10.1016/j.immuni.2014.06.008

Azizi E, Carr AJ, Plitas G, et al., 2018, Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell, 174()5: 1293–1308.e36.

https://doi.org/10.1016/j.cell.2018.05.060

Vitale I, Shema E, Loi S, et al., 2021, Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med, 27(2): 212–224.

https://doi.org/10.1038/s41591-021-01233-9

Singhal S, Stadanlick J, Annunziata MJ, et al., 2019, Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med, 11(479): eaat1500.

https://doi.org/10.1126/scitranslmed.aat1500

Laviron M, Boissonnas A, 2019, Ontogeny of tumor-associated macrophages. Front Immunol, 10: 1799.

Müller S, Kohanbash G, Liu SJ, et al., 2017, Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol, 18: 234.

Bowman RL, Klemm F, Akkari L, et al., 2016, Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep, 17(9): 2445–2459.

https://doi.org/10.1016/j.celrep.2016.10.052

Balkwill F, Mantovani A, 2001, Inflammation and cancer: Back to virchow? Lancet, 357(9255): 539–545.

https://doi.org/10.1016/S0140-6736(00)04046-0

Kumar V, Patel S, Tcyganov E, et al., 2016, The nature of Myeloid-Derived suppressor cells in the tumor microenvironment. Trends Immunol, 37(3): 208–220.

https://doi.org/10.1016/j.it.2016.01.004

Kumar V, Cheng P, Condamine T, et al., 2016, CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity, 44(2): 303–315.

https://doi.org/10.1016/j.immuni.2016.01.014

Laoui D, Keirsse J, Morias Y, et al., 2016, The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun, 7: 13720.

https://doi.org/10.1038/ncomms13720

Veglia F, Gabrilovich DI, 2017, Dendritic cells in cancer: The role revisited. Curr Opin Immunol, 45: 43–51.

https://doi.org/10.1016/j.coi.2017.01.002

Broz ML, Binnewies M, Boldajipour B, et al., 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell, 26(5): 638–652.

https://doi.org/10.1016/j.ccell.2014.09.007

He YF, Wang CQ, Yu Y, et al., 2015, Tie2-expressing monocytes are associated with identification and prognoses of hepatitis B virus related hepatocellular carcinoma after resection. PLoS One, 10(11): e0143657.

https://doi.org/10.1371/journal.pone.0143657

Awad RM, De Vlaeminck Y, Maebe J, et al., 2018, Turn back the TIMe: Targeting tumor infiltrating myeloid cells to revert cancer progression. Front Immunol, 9: 1977.

https://doi.org/10.3389/fimmu.2018.01977

Nywening TM, Wang-Gillam A, Sanford DE, et al., 2016, Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol, 17(5): 651–662.

https://doi.org/10.1016/S1470-2045(16)00078-4

Bonapace L, Coissieux MM, Wyckoff J, et al., 2014, Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature, 515(7525): 130–133.

https://doi.org/10.1038/nature13862

Steggerda SM, Bennett MK, Chen J, et al., 2017, Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother. Cancer, 5(1): 101.

https://doi.org/10.1186/s40425-017-0308-4

Nefedova Y, Fishman M, Sherman S, et al., 2007, Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res, 67(22): 11021–11028.

https://doi.org/10.1158/0008-5472.CAN-07-2593

Vincent J, Mignot G, Chalmin F, et al, 2010, 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res, 70(8): 3052–3061.

https://doi.org/10.1158/0008-5472.CAN-09-3690

Dempke WC, Fenchel K, Uciechowski P, et al., 2017, Second-and third-generation drugs for immuno-oncology treatment-the more the better? Eur J Cancer, 74: 55–72.

https://doi.org/10.1016/j.ejca.2017.01.001

Mellman I, Coukos G, Dranoff G, 2011, Cancer immunotherapy comes of age. Nature, 480(7378): 480–489.

https://doi.org/10.1038/nature10673

Drake CG, Jaffee E, Pardoll DM, 2006, Mechanisms of immune evasion by tumors. Adv Immunol, 90: 51–81.

https://doi.org/10.1016/S0065-2776(06)90002-9

van der Leun AM, Thommen DS, Schumacher TN, 2020, CD8 T cell states in human cancer: Insights from single-cell analysis. Nat Rev Cancer, 20(4): 218–232.

https://doi.org/10.1038/s41568-019-0235-4

Ribas A, Wolchok JD, 2018, Cancer immunotherapy using checkpoint blockade. Science (New York), 359(6382): 1350– 1355.

https://doi.org/10.1126/science.aar4060

Keir ME, Butte MJ, Freeman GJ, et al., 2008, PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 26: 677–704.

https://doi.org/10.1146/annurev.immunol.26.021607.090331

Topalian SL, Drake CG, Pardoll DM, 2015, Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 27(4): 450–461.

https://doi.org/10.1016/j.ccell.2015.03.001

Schetters ST, Rodriguez E, Kruijssen LJ, et al., 2020, Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. J Immunother Cancer, 8(2): e000588.

https://doi.org/10.1136/jitc-2020-000588

Hugo W, Zaretsky JM, Sun L, et al., 2016, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 165(1): 35–44.

https://doi.org/10.1016/j.cell.2016.02.065

Hamid O, Robert C, Daud A, et al., 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 369(2): 134–144.

https://doi.org/10.1056/NEJMoa1305133

Das S, Camphausen K, Shankavaram U, 2020, Cancer-specific immune prognostic signature in solid tumors and its relation to immune checkpoint therapies. Cancers, 12(9): 2476.

https://doi.org/10.3390/cancers12092476

Marcovecchio PM, Thomas G, Salek-Ardakani S, 2021, CXCL9-expressing tumor-associated macrophages: New players in the fight against cancer. J Immunother Cancer, 9(2): e002045.

https://doi.org/10.1136/jitc-2020-002045

Huber V, Di Guardo L, Lalli L, et al., 2021, Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. J Immunother Cancer, 9(2): e001167.

https://doi.org/10.1136/jitc-2020-001167

Gordon SR, Maute RL, Dulken BW, et al., 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 545(7655): 495–499.

https://doi.org/10.1038/nature22396

Zou W, Wolchok JD, Chen L, 2016, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 8(328): 328–324.

https://doi.org/10.1126/scitranslmed.aad7118

Liu M, Zhou J, Liu X, et al., 2020, Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut, 69(2): 365–379.

https://doi.org/10.1136/gutjnl-2018-317257

Escobar G, Barbarossa L, Barbiera G, et al., 2018, Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. Nat Commun, 9: 2896.

Gubin MM, Esaulova E, Ward JP, et al., 2018, High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell, 175(4): 1443.

https://doi.org/10.1016/j.cell.2018.09.030

Yin M, Guo Y, Hu R, et al., 2020, Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun, 11(1): 1833.

https://doi.org/10.1038/s41467-020-15290-0

June CH, Sadelain M, 2018, Chimeric antigen receptor therapy. N Engl J Med, 379(1): 64–73.

https://doi.org/10.1056/NEJMra1706169

Green DS, Nunes AT, David-Ocampo V, et al., 2018, A phase 1 trial of autologous monocytes stimulated ex vivo with sylatron (peginterferon alfa-2b) and actimmune (interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. J Transl Med, 16(1): 196.

https://doi.org/10.1186/s12967-018-1569-5

Liu Y, Cao X, 2015, The origin and function of tumor-associated macrophages. Cell Mol Immunol, 12: 1–4.

https://doi.org/10.1038/cmi.2014.83

Noy R, Pollard JW, 2014, Tumor-associated macrophages: From mechanisms to therapy. Immunity, 41(1): 49–61.

https://doi.org/10.1016/j.immuni.2014.06.010